Cargando…
The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture
Tumor immune escape is associated with the loss of tumor HLA class I (HLA-I) expression commonly found in malignant cells. Accumulating evidence suggests that the efficacy of immunotherapy depends on the expression levels of HLA class I molecules on tumors cells. It also depends on the molecular mec...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371743/ https://www.ncbi.nlm.nih.gov/pubmed/28264447 http://dx.doi.org/10.3390/vaccines5010007 |
_version_ | 1782518482171068416 |
---|---|
author | Garrido, Federico Perea, Francisco Bernal, Mónica Sánchez-Palencia, Abel Aptsiauri, Natalia Ruiz-Cabello, Francisco |
author_facet | Garrido, Federico Perea, Francisco Bernal, Mónica Sánchez-Palencia, Abel Aptsiauri, Natalia Ruiz-Cabello, Francisco |
author_sort | Garrido, Federico |
collection | PubMed |
description | Tumor immune escape is associated with the loss of tumor HLA class I (HLA-I) expression commonly found in malignant cells. Accumulating evidence suggests that the efficacy of immunotherapy depends on the expression levels of HLA class I molecules on tumors cells. It also depends on the molecular mechanism underlying the loss of HLA expression, which could be reversible/“soft” or irreversible/“hard” due to genetic alterations in HLA, β2-microglobulin or IFN genes. Immune selection of HLA-I negative tumor cells harboring structural/irreversible alterations has been demonstrated after immunotherapy in cancer patients and in experimental cancer models. Here, we summarize recent findings indicating that tumor HLA-I loss also correlates with a reduced intra-tumor T cell infiltration and with a specific reorganization of tumor tissue. T cell immune selection of HLA-I negative tumors results in a clear separation between the stroma and the tumor parenchyma with leucocytes, macrophages and other mononuclear cells restrained outside the tumor mass. Better understanding of the structural and functional changes taking place in the tumor microenvironment may help to overcome cancer immune escape and improve the efficacy of different immunotherapeutic strategies. We also underline the urgent need for designing strategies to enhance tumor HLA class I expression that could improve tumor rejection by cytotoxic T-lymphocytes (CTL). |
format | Online Article Text |
id | pubmed-5371743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-53717432017-04-10 The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture Garrido, Federico Perea, Francisco Bernal, Mónica Sánchez-Palencia, Abel Aptsiauri, Natalia Ruiz-Cabello, Francisco Vaccines (Basel) Review Tumor immune escape is associated with the loss of tumor HLA class I (HLA-I) expression commonly found in malignant cells. Accumulating evidence suggests that the efficacy of immunotherapy depends on the expression levels of HLA class I molecules on tumors cells. It also depends on the molecular mechanism underlying the loss of HLA expression, which could be reversible/“soft” or irreversible/“hard” due to genetic alterations in HLA, β2-microglobulin or IFN genes. Immune selection of HLA-I negative tumor cells harboring structural/irreversible alterations has been demonstrated after immunotherapy in cancer patients and in experimental cancer models. Here, we summarize recent findings indicating that tumor HLA-I loss also correlates with a reduced intra-tumor T cell infiltration and with a specific reorganization of tumor tissue. T cell immune selection of HLA-I negative tumors results in a clear separation between the stroma and the tumor parenchyma with leucocytes, macrophages and other mononuclear cells restrained outside the tumor mass. Better understanding of the structural and functional changes taking place in the tumor microenvironment may help to overcome cancer immune escape and improve the efficacy of different immunotherapeutic strategies. We also underline the urgent need for designing strategies to enhance tumor HLA class I expression that could improve tumor rejection by cytotoxic T-lymphocytes (CTL). MDPI 2017-02-27 /pmc/articles/PMC5371743/ /pubmed/28264447 http://dx.doi.org/10.3390/vaccines5010007 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Garrido, Federico Perea, Francisco Bernal, Mónica Sánchez-Palencia, Abel Aptsiauri, Natalia Ruiz-Cabello, Francisco The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture |
title | The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture |
title_full | The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture |
title_fullStr | The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture |
title_full_unstemmed | The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture |
title_short | The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture |
title_sort | escape of cancer from t cell-mediated immune surveillance: hla class i loss and tumor tissue architecture |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371743/ https://www.ncbi.nlm.nih.gov/pubmed/28264447 http://dx.doi.org/10.3390/vaccines5010007 |
work_keys_str_mv | AT garridofederico theescapeofcancerfromtcellmediatedimmunesurveillancehlaclassilossandtumortissuearchitecture AT pereafrancisco theescapeofcancerfromtcellmediatedimmunesurveillancehlaclassilossandtumortissuearchitecture AT bernalmonica theescapeofcancerfromtcellmediatedimmunesurveillancehlaclassilossandtumortissuearchitecture AT sanchezpalenciaabel theescapeofcancerfromtcellmediatedimmunesurveillancehlaclassilossandtumortissuearchitecture AT aptsiaurinatalia theescapeofcancerfromtcellmediatedimmunesurveillancehlaclassilossandtumortissuearchitecture AT ruizcabellofrancisco theescapeofcancerfromtcellmediatedimmunesurveillancehlaclassilossandtumortissuearchitecture AT garridofederico escapeofcancerfromtcellmediatedimmunesurveillancehlaclassilossandtumortissuearchitecture AT pereafrancisco escapeofcancerfromtcellmediatedimmunesurveillancehlaclassilossandtumortissuearchitecture AT bernalmonica escapeofcancerfromtcellmediatedimmunesurveillancehlaclassilossandtumortissuearchitecture AT sanchezpalenciaabel escapeofcancerfromtcellmediatedimmunesurveillancehlaclassilossandtumortissuearchitecture AT aptsiaurinatalia escapeofcancerfromtcellmediatedimmunesurveillancehlaclassilossandtumortissuearchitecture AT ruizcabellofrancisco escapeofcancerfromtcellmediatedimmunesurveillancehlaclassilossandtumortissuearchitecture |